Please provide your email address to receive an email when new articles are posted on . High hematocrit levels were observed among 8.4% of adults receiving gender-confirming testosterone therapy.

In the phase 3 VERIFY trial, rusfertide was associated with a significantly higher proportion of patients achieving clinical response compared with placebo.

Researchers explored the incidence of erythrocytosis in the first 20 months of testosterone therapy among people receiving gender-affirming hormone therapy (GAHT). Specifically, they conducted a ...

The use of testosterone as gender-affirming hormone therapy (GAHT) among transgender men is associated with a lower risk for erythrocytosis (abnormal blood cell elevation) than was previously reported ...

Rusfertide effectively maintained hematocrit control below 45% and reduced phlebotomy eligibility in PV patients through 52 weeks. Patients switching from placebo to rusfertide achieved rapid and ...

The FDA granted priority review to rusfertide, a potential therapy for polycythemia vera; a decision regarding approval is ...

Please provide your email address to receive an email when new articles are posted on . Rusfertide reduced need for phlebotomies and offered better hematocrit control than placebo. Results showed ...

Rusfertide effectively maintains hematocrit control and reduces phlebotomy need in PV patients, as shown in the VERIFY study over 52 weeks. The therapy, a hepcidin mimetic peptide, regulates iron ...

ORLANDO, Fla. — Rusfertide, a weekly self-injected peptide, maintained control of hematocrit levels and reductions in phlebotomy requirements through 52 weeks in patients with polycythemia vera (PV), ...

When a newborn has polycythemia, it means they have too many red blood cells. A doctor typically diagnoses polycythemia using a hematocrit test. Polycythemia can lead to thickening of the blood and ...